

Journal of Nephrologist

The effects of vitamin D on the renin-angiotensin system

Sahar Ajabshir¹, Arif Asif², Ali Nayer^{3,*}

¹Department of Dietetics and Nutrition, Florida International University, Miami, USA

²Division of Nephrology and Hypertension, Albany Medical College, Albany, USA

³Division of Nephrology and Hypertension, University of Miami, Miami, USA

ARTICLE INFO

Article type:

Editorial

Article history:

Received: 15 December 2013

Accepted: 25 December 2013

Published online: 1 April 2014

DOI: 10.12860/jnp.2014.09

Keywords:

Vitamin D

Renin-angiotensin system

Blood pressure

Hypertension

Implication for health policy/practice/research/medical education:

The current literature indicates that maintaining adequate vitamin D levels may be an important consideration in the treatment of hypertension, especially in individuals with vitamin D insufficiency and deficiency.

Please cite this paper as: Ajabshir S, Asif A, Nayer A. The effects of vitamin D on the renin-angiotensin system. J Nephrologist. 2014; 3(2): 41-43. DOI: 10.12860/jnp.2014.09

In humans, 80-90% of required vitamin D is made in the skin upon sun exposure and the remaining 10-20% is ingested in fish, eggs and fortified dairy products. In the liver, vitamins D₂(ergocalciferol) and D₃(cholecalciferol) are converted into 25-hydroxyvitamin D₂ (25[OH]D₂) and 25-hydroxyvitamin D₃ (25[OH]D₃), respectively (1). In the kidney, 25(OH)D is converted to its biologically active form 1,25-dihydroxyvitamin D (1,25[OH]₂D) by 1 α -hydroxylase. The serum level of 25(OH)D is used to determine vitamin D status and normally ranges between 30-100 ng/mL (75–250 nmol/L). Vitamin D insufficiency and deficiency are defined as serum 25(OH)D levels of 20-30 mg/dL (50-75 nmol/L) and <20 ng/mL (50 nmol/L), respectively (2). The critical role of 1,25(OH)₂D in calcium and phosphorus homeostasis is well established (1,2). Accumulating evidence indicates that vitamin D also plays an important role in regulating the blood pressure.

A recent randomized, double-blind, placebo controlled study conducted by Nasri *et al.* demonstrated that oral supplementation of vitamin D led to a decrease in the blood pressure in individuals with diabetes mellitus (3). Sixty individuals were randomized to receive either vitamin D₃ 50,000 IU per week (n=30) or placebo (n=30) for 12 weeks. Five individuals (8.3%) had vitamin D deficiency and 27 others (45%) had vitamin D insufficiency. Vitamin D supplementation increased serum 25(OH)D levels from 84 \pm 52 nmol/L to 164 \pm 57 nmol/L (P= 0.001). Vitamin D supplementation led to a decrease in both systolic (121 \pm 13 to 110 \pm 9 mm Hg; P= 0.001) and diastolic blood pressure (81 \pm 8 to 76 \pm 7 mm Hg, P= 0.046). No statistically significant change in blood pressure was observed in the placebo group.

The pivotal role of the renin-angiotensin system in the regulation of the blood pressure is well established (Figure 1). Renin is secreted by the juxtaglomerular cells of the kidney in response

*Corresponding author: Ali Nayer, Division of Nephrology and Hypertension, University of Miami, Clinical Research Building, suite 825, 1120 NW 14th St., Miami, FL 33136, USA. Tel: 305.243.3583, fax: 305.243.3506, E-mail: anayer@med.miami.edu




Figure 1. The effects of vitamin D on the renin-angiotensin system. 1,25-dihydroxyvitamin D suppresses renin gene expression, thereby inhibiting the renin-angiotensin system. ACE, angiotensin-converting enzyme; H₂O, water; Na, sodium.

to decreased renal blood flow. It converts plasma angiotensinogen to angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme. Angiotensin II leads to increased water and sodium reabsorption in the kidney and vasoconstriction. Mounting evidence indicates that vitamin D regulates the renin-angiotensin system. An inverse relationship between the blood pressure and serum 25(OH)D levels has been documented in a number of the epidemiological studies (4,5). In a cross-sectional study, Forman *et al.* explored the relation between 25(OH)D and the renin-angiotensin system in 184 individuals with normal blood pressure (6). Compared with vitamin D-sufficient individuals, those with vitamin D deficiency and insufficiency had greater plasma angiotensin II levels and a trend for higher plasma renin activity. In addition, the activity of the renin-angiotensin system in the kidney, as measured by the renal plasma flow in response to angiotensin II infusion, was greater in vitamin D-deficient than in

vitamin D-sufficient individuals. These results suggested that decreased plasma 25(OH)D levels were associated with increased activity of the renin-angiotensin system. Resnick *et al.* investigated the relation between the plasma renin activity and calcium-regulating hormones including calcitonin, 1,25(OH)₂D₃ and parathyroid hormone in 51 individuals with essential hypertension (7). An inverse relation of the serum 1,25(OH)₂D₃ level to the plasma renin activity ($r = -0.65, P < 0.001$) was observed. This study corroborated a link between calcium homeostasis, vitamin D metabolism and the renin-angiotensin system.

To unravel the molecular mechanisms involved in vitamin D-mediated regulation of the renin-angiotensin system, mice with loss-of-function mutations involving vitamin D receptor gene (VDR-null mice) were examined. The VDR-null mice develop hypocalcemia at 3 weeks of age, hyperparathyroidism, rickets and osteomalacia (8). Li *et al.* demonstrated that renin gene expression in the kidney and angiotensin II levels in the plasma were substantially increased in the VDR-null mice leading to hypertension and cardiac hypertrophy (9). In wild-type mice, pharmacological inhibition of 1,25(OH)₂D₃ synthesis led to an increase in renin gene expression, whereas 1,25(OH)₂D₃ treatment suppressed renin expression. Similarly, 1,25(OH)₂D₃ markedly suppressed renin gene expression in cultured cells by a VDR-mediated mechanism. These investigators also demonstrated that the effect of vitamin D on renin gene expression was independent of calcium metabolism. The authors concluded that 1,25(OH)₂D₃ is a negative regulator of the renin-angiotensin system. Subsequently, it was shown that 1,25(OH)₂D₃ suppressed renin gene expression by binding to the transcription factor cAMP response element-binding protein (CREB), thereby suppressing the activity of the cAMP response element in the renin gene promoter (10). To determine whether the inhibitory effects of 1,25(OH)₂D on the renin-angiotensin system is dependent on calcium or phosphorous, Zhou *et al.* examined the effects of dietary interventions

in 1α -hydroxylase knockout mice. Phenotypically resembling VDR-null mice, 1α -hydroxylase knockout mice demonstrate undetectable serum $1,25(\text{OH})_2\text{D}$ levels and develop hypocalcemia, hypophosphatemia, secondary hyperparathyroidism, growth retardation and skeletal abnormalities characteristic of rickets (11). Zhou *et al.* demonstrated that 1α -hydroxylase knockout mice developed hypertension and cardiac hypertrophy associated with the activation of the renin-angiotensin system in the kidney and heart (12). Despite the normalization of the serum calcium and phosphorus levels, a calcium- and phosphorus-fortified diet neither normalized the blood pressure nor suppressed the activity of the renin-angiotensin system in the 1α -hydroxylase knockout mice. However, $1,25(\text{OH})_2\text{D}$ treatment led to the normalization of the activity of the renin-angiotensin system and blood pressure. In summary, the current literature indicates that maintaining adequate vitamin D levels may be an important consideration in the treatment of hypertension, especially in individuals with vitamin D insufficiency and deficiency.

Authors' contributions

All authors wrote the paper equally.

Conflict of interests

Authors declare no conflicts of interest.

Funding/Support

This work received no funding from public, commercial or not-for-profit organizations.

References

- Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. *Am J Physiol Renal Physiol* 2005; 289(1): F8-28.
- Holick MF. Vitamin D deficiency. *N Engl J Med* 2007; 357(3): 266-81.
- Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaei M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a randomized, double-blind, placebo controlled clinical trial. *J Nephropathol* 2014; 3(1):29-33.
- Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. *Am J Hypertens* 2007; 20(7):713-9.
- Hintzpeter B, Mensink GB, Thierfelder W, Müller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. *Eur J Clin Nutr* 2008; 62(9): 1079-89.
- Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. *Hypertension* 2010; 55(5):1283-8.
- Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. *Ann Intern Med* 1986; 105(5):649-54.
- Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, *et al.* Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. *Proc Natl Acad Sci U S A* 1997; 94(18):9831-5.
- Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. $1,25$ -Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002; 110(2):229-38.
- Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, *et al.* $1,25$ -dihydroxyvitamin D₃ suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. *J Biol Chem* 2007; 282(41): 29821-30.
- Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, *et al.* Targeted ablation of the 25-hydroxyvitamin D 1α -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. *Proc Natl Acad Sci U S A* 2001; 98(13): 7498-503.
- Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and $1,25(\text{OH})_2\text{D}_3$ -dependent regulation of the renin-angiotensin system in 1α -hydroxylase knockout mice. *Kidney Int* 2008; 74(2): 170-9.